Regulatory

May 19, 2022

Report from Annual General Meeting in Affibody Medical AB (publ)

Solna, Sweden, May 19, 2022 – Affibody Medical AB (publ) today held its Annual General Meeting. The following resolutions were adopted. Adoption of the income statement and the balance...

Read more

Regulatory

January 12, 2022

Lokon Pharma and Affibody Initiates a Collaboration to Develop Novel Cancer Therapeutics

Uppsala and Solna, Sweden, January 12, 2022. Lokon Pharma AB, a leading biotech company in the area of immunostimulatory gene therapy for cancer delivered by uniquely engineered oncolytic viruses,...

Read more

Regulatory

December 9, 2021

Phase 2 HER2-targeting Study Presented at SABCS

Solna, Sweden, December 9, 2021. Affibody AB (“Affibody”) today announced that results of the Phase 2 study “A phase II study of 68Ga-ABY-025 PET for non-invasive quantification of HER2...

Read more

Regulatory

November 16, 2021

Affibody enters agreement with ACELYRIN for the development and commercialization of izokibep at a total deal value of USD 305 million plus royalties

Solna, Sweden, November 16, 2021. Affibody AB today announced a partnership agreement with ACELYRIN, INC., (“ACELYRIN”) to develop and commercialize izokibep, a bispecific molecule targeting interleukin-17A (IL-17), for multiple...

Read more